CN1620435A - 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 - Google Patents

4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 Download PDF

Info

Publication number
CN1620435A
CN1620435A CNA028141709A CN02814170A CN1620435A CN 1620435 A CN1620435 A CN 1620435A CN A028141709 A CNA028141709 A CN A028141709A CN 02814170 A CN02814170 A CN 02814170A CN 1620435 A CN1620435 A CN 1620435A
Authority
CN
China
Prior art keywords
compound
phenyl
piperidin
amino
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028141709A
Other languages
English (en)
Chinese (zh)
Inventor
W·布朗
A·格里芬
C·瓦尔波尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1620435A publication Critical patent/CN1620435A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA028141709A 2001-05-18 2002-05-16 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用 Pending CN1620435A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE01017706 2001-05-18
SE0101770A SE0101770D0 (sv) 2001-05-18 2001-05-18 Novel compounds

Publications (1)

Publication Number Publication Date
CN1620435A true CN1620435A (zh) 2005-05-25

Family

ID=20284173

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028141709A Pending CN1620435A (zh) 2001-05-18 2002-05-16 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用

Country Status (25)

Country Link
US (1) US7064137B2 (enExample)
EP (1) EP1395558B1 (enExample)
JP (1) JP2005510456A (enExample)
KR (1) KR20040000469A (enExample)
CN (1) CN1620435A (enExample)
AR (1) AR033759A1 (enExample)
AT (1) ATE313529T1 (enExample)
BG (1) BG108331A (enExample)
BR (1) BR0209669A (enExample)
CA (1) CA2446313A1 (enExample)
CO (1) CO5540319A2 (enExample)
CZ (1) CZ20033090A3 (enExample)
DE (1) DE60208193T2 (enExample)
EE (1) EE200300534A (enExample)
HU (1) HUP0401608A2 (enExample)
IL (1) IL158629A0 (enExample)
IS (1) IS7031A (enExample)
MX (1) MXPA03010441A (enExample)
NO (1) NO20035112D0 (enExample)
PL (1) PL366390A1 (enExample)
RU (1) RU2003131967A (enExample)
SE (1) SE0101770D0 (enExample)
SK (1) SK13922003A3 (enExample)
WO (1) WO2002094783A1 (enExample)
ZA (1) ZA200308637B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554100A (zh) * 2023-02-22 2023-08-08 江苏师范大学 一种钯催化合成菲啶酮类化合物的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300987D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
KR20140015122A (ko) 2003-10-01 2014-02-06 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
WO2016099394A1 (en) * 2014-12-19 2016-06-23 Pharmnovo Ab Novel selective delta-opioid receptor agonists useful for the treatment of pain, anxiety and depression.
US20250084091A1 (en) * 2021-05-04 2025-03-13 The Texas A&M University System Inhibitors of sars-cov-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091096A (en) * 1976-03-19 1978-05-23 Eli Lilly And Company Dinitroanilines for the control of phytopathogens
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
US4252812A (en) * 1977-05-23 1981-02-24 Pfizer Inc. 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles
SE441448B (sv) 1977-05-23 1985-10-07 Pfizer Sett att framstella hexahydro-gamma-karbolinforeningar
DE3200304A1 (de) * 1981-01-16 1982-08-26 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
DE3563964D1 (en) * 1984-10-16 1988-09-01 Synthelabo Piperidine derivatives, their preparation and their therapeutical application
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
KR940003491B1 (ko) * 1989-08-10 1994-04-23 리히터 게데온 베기에스제티 기아르 알.티 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
CA2316341A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
JP4498602B2 (ja) 1998-03-10 2010-07-07 リサーチ・トライアングル・インスティチュート 新規なオピエート化合物、その調製法及び使用法
SE9904675D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
US6552036B2 (en) * 2000-03-03 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
US6556387B1 (en) * 2000-03-31 2003-04-29 Seagate Technology Llc Controlling mechanical response characteristics of a disc drive actuator by adjusting a fastener engaging the actuator shaft to vary axial force on the bearing assembly
SE0001207D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116554100A (zh) * 2023-02-22 2023-08-08 江苏师范大学 一种钯催化合成菲啶酮类化合物的方法

Also Published As

Publication number Publication date
SE0101770D0 (sv) 2001-05-18
EP1395558A1 (en) 2004-03-10
BR0209669A (pt) 2004-04-20
ATE313529T1 (de) 2006-01-15
RU2003131967A (ru) 2005-05-10
NO20035112D0 (no) 2003-11-17
US7064137B2 (en) 2006-06-20
EE200300534A (et) 2004-02-16
KR20040000469A (ko) 2004-01-03
EP1395558B1 (en) 2005-12-21
IL158629A0 (en) 2004-05-12
CA2446313A1 (en) 2002-11-28
DE60208193D1 (de) 2006-01-26
JP2005510456A (ja) 2005-04-21
ZA200308637B (en) 2005-02-07
IS7031A (is) 2003-11-13
DE60208193T2 (de) 2006-07-13
MXPA03010441A (es) 2004-03-09
SK13922003A3 (sk) 2004-04-06
CO5540319A2 (es) 2005-07-29
US20040152731A1 (en) 2004-08-05
BG108331A (bg) 2004-10-29
WO2002094783A1 (en) 2002-11-28
PL366390A1 (en) 2005-01-24
HUP0401608A2 (hu) 2004-12-28
CZ20033090A3 (en) 2004-06-16
AR033759A1 (es) 2004-01-07

Similar Documents

Publication Publication Date Title
CN1527820A (zh) 4-(苯基-(哌嗪基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN1692100A (zh) 4－[哌啶－4－亚基－(3－氨基甲酰苯基)甲基]苯甲酰胺衍生物及其在治疗疼痛、脊椎损伤或胃肠疾病方面的应用
CN1182134C (zh) 用于治疗疼痛的喹啉基-亚哌啶-4-基-甲基-苯甲酰胺衍生物
CN1509271A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
CN1608064A (zh) 新化合物
CN1422266A (zh) 用于治疗疼痛的羟苯基－哌嗪基－甲基－苯甲酰胺衍生物
CN1639123A (zh) 4－(苯基－(哌啶－4－基)－氨基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠道疾病中的应用
US7186733B2 (en) 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
CN1527828A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
CN1547579A (zh) 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途
EP1395558B1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
CN1527818A (zh) 4-(苯基-(哌啶-4-基)-氨基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
AU2002305993A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002309373A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002305995A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002305984A1 (en) 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication